GlassScriptPhysician profile
John William Roberts
NPI 1700856978
$17,650.80
in general payments reported to CMS, 2019-2025
84 companies · $1,747 in 2025
The $1,747 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,610 · 2020: $2,028 · 2021: $3,271 · 2022: $2,613 · 2023: $2,436 · 2024: $2,945 · 2025: $1,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,128.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,742.18 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Pfizer INC. | $1,215.77 | 2019-2025 | |
| Amgen INC. | $1,062.66 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $904.38 | 2019-2025 | Shingrix, Bexsero, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $829.32 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $668.81 | 2019-2024 | Xarelto, Spravato |
| Esperion Therapeutics, INC. | $659.36 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $629.34 | 2019-2025 | Jardiance, Synjardy |
| Otsuka America Pharmaceutical, INC. | $551.64 | 2019-2025 | Rexulti |
| Allergan, INC. | $538.01 | 2019-2020 | |
| Novo Nordisk INC | $534.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bausch Health US, LLC | $456.41 | 2019-2024 | Aplenzin, Wellbutrin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $429.29 | 2019-2024 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $401.30 | 2019-2024 | Austedo Xr, Ajovy |
| Almatica Pharma LLC | $380.26 | 2021-2024 | Loreev Xr, Gralise, Teriparatide |
Show all 84 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.